Developing and advancing dry powder inhalation towards enhanced therapeutics

S. Stegemann, S. Kopp, G. Borchard, V. P. Shah, S. Senel, R. Dubey, N. Urbanetz, M. Cittero, A. Schoubben, C. Hippchen, D. Cade, A. Fuglsang, J. Morais, L. Borgström, F. Farshi, K. H. Seyfang, R. Hermann, A. Van De Putte, I. Klebovich, A. Hincal

Research output: Contribution to journalReview article

48 Citations (Scopus)


Enhanced therapeutics are drug products derived from existing generic drugs that provide additional benefits to the patients and the healthcare system. Enhanced therapeutics are considered to be an important and relatively low risk source of innovation. Pulmonary drug delivery is the major delivery route to treat chronic respiratory diseases and has been proven as a potential delivery route for complex drugs that cannot be delivered orally. Development of dry powder inhalation systems targets the delivery of fine drug particles to the deep lung surface by a combination of drug formulation, primary packaging and a device, whereby each contributes to the overall performance. Various methodologies for the non-clinical and clinical performance testing of orally inhaled products have been proposed and applied with variable success. Regulatory pathways have been developed and applied since. Considerable efforts have been made during the past decade to understand and optimize pulmonary drug delivery including their efficient commercial manufacturing. Pulmonary drug delivery remains an area of future innovation in the effective treatment of pulmonary diseases as well as the systemic delivery of systemically active complex drugs.

Original languageEnglish
Pages (from-to)181-194
Number of pages14
JournalEuropean Journal of Pharmaceutical Sciences
Issue number1-2
Publication statusPublished - Jan 23 2013


  • Affordable medicines
  • Bioequivalence
  • Chronic respiratory disease
  • Dry powder inhalation
  • Inhalation therapy
  • Orally inhaled products

ASJC Scopus subject areas

  • Pharmaceutical Science

Fingerprint Dive into the research topics of 'Developing and advancing dry powder inhalation towards enhanced therapeutics'. Together they form a unique fingerprint.

  • Cite this

    Stegemann, S., Kopp, S., Borchard, G., Shah, V. P., Senel, S., Dubey, R., Urbanetz, N., Cittero, M., Schoubben, A., Hippchen, C., Cade, D., Fuglsang, A., Morais, J., Borgström, L., Farshi, F., Seyfang, K. H., Hermann, R., Van De Putte, A., Klebovich, I., & Hincal, A. (2013). Developing and advancing dry powder inhalation towards enhanced therapeutics. European Journal of Pharmaceutical Sciences, 48(1-2), 181-194.